CDSCO approves antibody cocktail drug for restricted emergency use to treat mild Covid-19 cases
CDSCO approves use of antibodies cocktail drug (Casirivimab and Imdevimab) for restricted emergency use to treat mild to moderate Covid-19 in adults and paediatric patients.
advertisement
Health workers inspect Covid-19 patients at a hospital in New Delhi. (Photo credit: PTI).
The Indian regulatory body, Central Drugs Standards Control Organisation (CDSCO), has approved the use of antibodies cocktail drug (Casirivimab and Imdevimab), for restricted emergency used to treat mild to moderate Covid-19 in adults and paediatric patients (12 years or weighing more than at least 40 kg).
Antibodies Cocktail Drug can be a game-changer in Covid-19 treatment, especially when these are recommended to be given at the early stages of laboratory-confirmed SARS-CoV-2 infection positive result. Theis is preferebly administered within 10 days of symptoms onset.
URL copied
representational image
During COVID 19 second wave in India, a number of people are seen hunting for oxygen cylinders, ICU beds and many more medical facilities across the country. Remdesivir is also one of the drugs many have been searching for their loved ones. So what is Remdesivir? Is this a life saving COVID 19 drug? Should it be given to every coronavirus positive patient? Can Remdesivir be given to COVID patients treated at home? Know all about it here:
According to an infographic video shared by PIB fact check, a verified Twitter account by the government of India to counter misinformation on govt. policies/schemes, Remdesivir is an experimental investigational drug that is granted for emergency authorisation use only. It is advisable for people who are moderately sick and are receiving oxygen. Furthermore, studies do not show mortality reduction with this drug. Moreover, Remdesivir is to be administered in hospitals settings only
This emergency use authorisation (EUA) will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla Limited.
Remdesivir now at Rs 899; producers cut prices post govt intervention
The National Pharmaceutical Pricing Authority under the Department of Pharmaceuticals declared change in prices for seven brands of Remdesivir injections of potency 100mg per vial
BusinessToday.In | April 17, 2021 | Updated 18:36 IST
Pharmaceutical companies manufacturing the anti-COVID medicine Remdesivir in India have voluntarily slashed prices following government intervention, National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals announced on Saturday. The authority declared change in prices for seven brands of Remdesivir injections of potency 100mg per vial.
According to an office memoradum by NPPA dated April 17, 2021, the prices have been slashed in the range of Rs 1,000 to Rs 2,700. After the price cuts, Cadila Healthcare s Remdac continues to be the cheapest Remdesivir injection at Rs 899. The injection was earlier being sold at Rs 2,800.
Small
Large
India is facing an acute shortage of Remdesivir, an injectable antiviral drug used in the treatment of Covid-19. The Centre has banned its export, states are shipping them in special flights, and anxious public have taken to social media to source it somehow. But how crucial is the drug really?
Dr Neeraj Nischal, additional professor, internal medicine, AIIMS, explains.
Q: How crucial is Remdesivir in the treatment of Covid patients? How does it work?
more stories